Next Generation Sequencing and ALS: known genes, different phenotyphes

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting motor neurons, leading to progressive paralysis.
• While most ALS cases are sporadic, 5-10% have a family history, indicating a genetic component.
• Recent advances in Next Generation Sequencing (NGS) have accelerated the discovery of genetic risk factors for ALS.

Purpose of the Study:

• To review the role of NGS in identifying genetic risk factors for both familial (fALS) and sporadic ALS (sALS).
• To highlight the discovery of shared genetic underpinnings between ALS and other neurological diseases.
• To focus on specific genes, including Valosin-containing protein (VCP) and Heterogeneous nuclear RNA-binding proteins (HNRNPA1, hnRNPA2B1), implicated in ALS and other neurodegenerative conditions.

Main Methods:

• Utilized Next Generation Sequencing (NGS) to identify disease-associated variants and genetic risk factors.
• Reviewed literature on genetic mutations identified through NGS in ALS patients.
• Focused on genes encoding VCP, HNRNPA1, and hnRNPA2B1, examining their association with ALS and other neurological diseases.

Main Results:

• NGS has significantly advanced the understanding of ALS genetic architecture.
• Mutations in approximately 20 genes have been identified, contributing to both familial and sporadic ALS.
• Genes like VCP, HNRNPA1, and hnRNPA2B1, identified via NGS, show mutations linked to ALS and other neurological disorders, suggesting shared disease mechanisms.

Conclusions:

• NGS is a powerful tool for discovering genetic risk factors in neurodegenerative diseases like ALS.
• The identification of shared genes and proteins across different neurological diseases points to overlapping pathological processes.
• Further research into these shared genetic factors may reveal novel therapeutic targets for ALS and related disorders.